Search

Your search keyword '"Levi ‐ Schaffer, Francesca"' showing total 868 results
Start Over Author "Levi ‐ Schaffer, Francesca"
868 results on '"Levi ‐ Schaffer, Francesca"'

7. Influence of FLG loss-of-function mutations in host–microbe interactions during atopic skin inflammation

Author

Oláh, Peter, Szlávicz, Eszter, Kuchner, Marcus, Nemmer, Jana, Zeeuwen, Patrick, Lefèvre-Utile, Alain, Fyhrquist, Nanna, Prast-Nielsen, Stefanie, Skoog, Tiina, Serra, Angela, Rodríguez, Elke, Raap, Ulrike, Meller, Stephan, Gyulai, Rolland, Hupé, Philippe, Kere, Juha, Levi-Schaffer, Francesca, Tsoka, Sophia, Alexander, Helen, Nestle, Frank O., Schröder, Jens M., Weidinger, Stephan, van den Bogaard, Ellen, Soumelis, Vassili, Greco, Dario, Barker, Jonathan, Lauerma, Antti, Ranki, Annamari, Andersson, Björn, Alenius, Harri, and Homey, Bernhard

Published
2022
Full Text
View/download PDF

12. Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper

Author

Pascal, Mariona, Bax, Heather J, Bergmann, Christoph, Bianchini, Rodolfo, Castells, Mariana, Chauhan, Jitesh, De Las Vecillas, Leticia, Hartmann, Karin, Álvarez, Elena Izquierdo, Jappe, Uta, Jimenez-Rodriguez, Teodorikez-Wilfox, Knol, Edward, Levi-Schaffer, Francesca, Mayorga, Cristobalina, Poli, Aurélie, Redegeld, Frank, Santos, Alexandra F, Jensen-Jarolim, Erika, Karagiannis, Sophia N, Pascal, Mariona, Bax, Heather J, Bergmann, Christoph, Bianchini, Rodolfo, Castells, Mariana, Chauhan, Jitesh, De Las Vecillas, Leticia, Hartmann, Karin, Álvarez, Elena Izquierdo, Jappe, Uta, Jimenez-Rodriguez, Teodorikez-Wilfox, Knol, Edward, Levi-Schaffer, Francesca, Mayorga, Cristobalina, Poli, Aurélie, Redegeld, Frank, Santos, Alexandra F, Jensen-Jarolim, Erika, and Karagiannis, Sophia N

Abstract

Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.

Published
2024

13. Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper

Author

CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Pascal, Mariona, Bax, Heather J, Bergmann, Christoph, Bianchini, Rodolfo, Castells, Mariana, Chauhan, Jitesh, De Las Vecillas, Leticia, Hartmann, Karin, Álvarez, Elena Izquierdo, Jappe, Uta, Jimenez-Rodriguez, Teodorikez-Wilfox, Knol, Edward, Levi-Schaffer, Francesca, Mayorga, Cristobalina, Poli, Aurélie, Redegeld, Frank, Santos, Alexandra F, Jensen-Jarolim, Erika, Karagiannis, Sophia N, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Pascal, Mariona, Bax, Heather J, Bergmann, Christoph, Bianchini, Rodolfo, Castells, Mariana, Chauhan, Jitesh, De Las Vecillas, Leticia, Hartmann, Karin, Álvarez, Elena Izquierdo, Jappe, Uta, Jimenez-Rodriguez, Teodorikez-Wilfox, Knol, Edward, Levi-Schaffer, Francesca, Mayorga, Cristobalina, Poli, Aurélie, Redegeld, Frank, Santos, Alexandra F, Jensen-Jarolim, Erika, and Karagiannis, Sophia N

Published
2024

14. Innovative Drugs for Allergies

Author

Tiligada, Ekaterini, Gerasimidou, Kyriaki, Levi-Schaffer, Francesca, Riccardi, Carlo, editor, Levi-Schaffer, Francesca, editor, and Tiligada, Ekaterini, editor

Published
2018
Full Text
View/download PDF

31. 2B4: A potential target in Staphylococcus aureus associated allergic inflammation.

Author

Gaur, Pratibha, Seaf, Mansour, Trabelsi, Nirit, Marcu, Orly, Gafarov, Daria, Schueler-Furman, Ora, Mandelboim, Ofer, Ben-Zimra, Micha, and Levi-Schaffer, Francesca

Subjects
STAPHYLOCOCCUS aureus, KILLER cells, ENZYME-linked immunosorbent assay, LYMPHOCYTE transformation, INFLAMMATION
Abstract

Staphylococcus aureus (SA) and its exotoxins activate eosinophils (Eos) and mast cells (MCs) via CD48, a GPI-anchored receptor belonging to the signaling lymphocytes activation molecules (SLAM) family. 2B4 (CD244), an immuno-regulatory transmembrane receptor also belonging to the SLAM family, is the high-affinity ligand for CD48. 2B4 is expressed on several leukocytes including NK cells, T cells, basophils, monocytes, dendritic cells (DCs), and Eos. In the Eos and MCs crosstalk carried out by physical and soluble interactions (named the 'allergic effector unit', AEU), 2B4–CD48 binding plays a central role. As CD48 and 2B4 share some structural characteristics and SA colonization accompanies most of the allergic diseases, we hypothesized that SA exotoxins (e.g. Staphylococcus enterotoxin B, SEB) can also bind and activate 2B4 and thereby possibly further aggravate inflammation. To check our hypothesis, we used in vitro, in silico, and in vivo methods. By enzyme-linked immunosorbent assay (ELISA), flow cytometry (FC), fluorescence microscopy, and microscale thermophoresis, we have shown that SEB can bind specifically to 2B4. By Eos short- and long-term activation assays, we confirmed the functionality of the SEB–2B4 interaction. Using computational modeling, we identified possible SEB-binding sites on human and mouse 2B4. Finally, in vivo, in an SEB-induced peritonitis model, 2B4-KO mice showed a significant reduction of inflammatory features compared with WT mice. Altogether, the results of this study confirm that 2B4 is an important receptor in SEB-mediated inflammation, and therefore a role is suggested for 2B4 in SA associated inflammatory conditions. In summary, we have shown a functional binding of SEB to cell surface expressed 2B4 in vitro , in silico , and in vivo. All these results strongly support the conclusion that 2B4 is an important receptor in SEB-mediated inflammation in allergy and beyond and therefore may constitute an interesting therapeutic target. Graphical Abstract [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases.

Author

Tiligada, Ekaterini, Gafarov, Daria, Zaimi, Maria, Vitte, Joana, and Levi-Schaffer, Francesca

Subjects
BIOTHERAPY, THERAPEUTIC use of monoclonal antibodies, SMALL molecules, IMMUNOMODULATORS, JANUS kinases, MAST cells, PROTEIN-tyrosine kinases, ALLERGIES, MOLECULAR structure
Abstract

The exponential rise in the prevalence of allergic diseases since the mid-twentieth century has led to a genuine public health emergency and has also fostered major progress in research on the underlying mechanisms and potential treatments. The management of allergic diseases benefits from the biological revolution, with an array of novel immunomodulatory therapeutic and investigational tools targeting players of allergic inflammation at distinct pathophysiological steps. Prominent examples include therapeutic monoclonal antibodies against cytokines, alarmins, and their receptors, as well as small-molecule modifiers of signal transduction mainly mediated by Janus kinases and Bruton's tyrosine kinases. However, the first-line therapeutic options have yet to switch from symptomatic to disease-modifying interventions. Here we present an overview of available drugs in the context of our current understanding of allergy pathophysiology, identify potential therapeutic targets, and conclude by providing a selection of candidate immunopharmacological molecules under investigation for potential future use in allergic diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell‐mediated diseases.

Author

Metz, Martin, Kolkhir, Pavel, Altrichter, Sabine, Siebenhaar, Frank, Levi‐Schaffer, Francesca, Youngblood, Bradford A., Church, Martin K., and Maurer, Marcus

Subjects
MAST cells, THERAPEUTICS, URTICARIA, MONOCLONAL antibodies, CELLULAR signal transduction, TRYPTASE
Abstract

Chronic urticaria (CU) is a mast cell (MC)‐dependent disease with limited therapeutic options. Current management strategies are directed at inhibiting IgE‐mediated activation of MCs and antagonizing effects of released mediators. Due to the complexity and heterogeneity of CU and other MC diseases and mechanisms of MC activation—including multiple activating receptors and ligands, diverse signaling pathways, and a menagerie of mediators—strategies of MC depletion or MC silencing (i.e., inhibition of MC activation via binding of inhibitory receptors) have been developed to overcome limitations of singularly targeted agents. MC silencers, such as agonist monoclonal antibodies that engage inhibitory receptors (e.g., sialic acid‐binding immunoglobulin‐like lectin8 ‐[Siglec‐8] [lirentelimab/AK002], Siglec‐6 [AK006], and CD200R [LY3454738]), have reached preclinical and clinical stages of development. In this review, we (1) describe the role of MCs in the pathogenesis of CU, highlighting similarities with other MC diseases in disease mechanisms and response to treatment; (2) explore current therapeutic strategies, categorized by nonspecific immunosuppression, targeted inhibition of MC activation or mediators, and targeted modulation of MC activity; and (3) introduce the concept of MC silencing as an emerging strategy that could selectively block activation of MCs without eliciting or exacerbating on‐ or off‐target, immunosuppressive adverse effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases

Author

Metcalfe, Dean D., Pawankar, Ruby, Ackerman, Steven J., Akin, Cem, Clayton, Frederic, Falcone, Franco H., Gleich, Gerald J., Irani, Anne-Marie, Johansson, Mats W., Klion, Amy D., Leiferman, Kristin M., Levi-Schaffer, Francesca, Nilsson, Gunnar, Okayama, Yoshimichi, Prussin, Calman, Schroeder, John T., Schwartz, Lawrence B., Simon, Hans-Uwe, Walls, Andrew F., and Triggiani, Massimo

Published
2016
Full Text
View/download PDF

37. Microbe-host interplay in atopic dermatitis and psoriasis

Author

Fyhrquist, Nanna, Muirhead, Gareth, Prast-Nielsen, Stefanie, Jeanmougin, Marine, Olah, Peter, Skoog, Tiina, Jules-Clement, Gerome, Feld, Micha, Barrientos-Somarribas, Mauricio, Sinkko, Hanna, van den Bogaard, Ellen H., Zeeuwen, Patrick L.J.M., Rikken, Gijs, Schalkwijk, Joost, Niehues, Hanna, Däubener, Walter, Eller, Silvia Kathrin, Alexander, Helen, Pennino, Davide, Suomela, Sari, Tessas, Ioannis, Lybeck, Emilia, Baran, Anna M., Darban, Hamid, Gangwar, Roopesh Singh, Gerstel, Ulrich, Jahn, Katharina, Karisola, Piia, Yan, Lee, Hansmann, Britta, Katayama, Shintaro, Meller, Stephan, Bylesjö, Max, Hupé, Philippe, Levi-Schaffer, Francesca, Greco, Dario, Ranki, Annamari, Schröder, Jens M., Barker, Jonathan, Kere, Juha, Tsoka, Sophia, Lauerma, Antti, Soumelis, Vassili, Nestle, Frank O., Homey, Bernhard, Andersson, Björn, and Alenius, Harri

Published
2019
Full Text
View/download PDF

50. Selected recent advances in understanding the role of human mast cells in health and disease

Author

Afd Pharmacology, Levi-Schaffer, Francesca, Gibbs, Bernhard F, Hallgren, Jenny, Pucillo, Carlo, Redegeld, Frank, Siebenhaar, Frank, Vitte, Joana, Mezouar, Soraya, Michel, Moïse, Puzzovio, Pier Giorgio, Maurer, Marcus, Afd Pharmacology, Levi-Schaffer, Francesca, Gibbs, Bernhard F, Hallgren, Jenny, Pucillo, Carlo, Redegeld, Frank, Siebenhaar, Frank, Vitte, Joana, Mezouar, Soraya, Michel, Moïse, Puzzovio, Pier Giorgio, and Maurer, Marcus

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results